Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

Phase 2

Terminated

Conditions: JOB's Syndrome
Hyper-IgE Recurrent Infection Syndrome
Immune Deficiency

Interventions: Drug: Ranitidine
Drug: Placebo

First Posted Date: 2007-09-11

Last Posted Date: 2013-02-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT00527878

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Proleukin and Rapamune in Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: IL-2
Drug: Rapamycin

First Posted Date: 2007-09-06

Last Posted Date: 2017-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9

Registration Number: NCT00525889

Locations: 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States
🇺🇸
Benaroya Research Institute, Seattle, Washington, United States

SARS Survivor Evaluations

Withdrawn

Conditions: Coronavirus (SARS-CoV)

First Posted Date: 2007-08-31

Last Posted Date: 2013-04-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00523276

Locations: 🇨🇳
Beijing Ditan Hospital, Beijing, Beijing, China
🇨🇳
Beijing You'An Hospital, Beijing, Beijing, China

Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants

Phase 4

Conditions: Catheterization

Interventions: Device: 3.15% chlorhexidine as daily antiseptic on needleless access port

First Posted Date: 2007-08-15

Last Posted Date: 2008-05-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 150

Registration Number: NCT00516360

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir (MK-0518)
Drug: Placebo

First Posted Date: 2007-08-14

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 53

Registration Number: NCT00515827

Locations: 🇺🇸
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
🇺🇸
Pitt CRS, Pittsburgh, Pennsylvania, United States
🇺🇸
MetroHealth CRS, Cleveland, Ohio, United States

and more 17 locations

Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

Phase 1

Completed

Conditions: Influenza
Virus Diseases

Interventions: Biological: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)

First Posted Date: 2007-08-14

Last Posted Date: 2015-05-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 22

Registration Number: NCT00516035

Locations: 🇺🇸
Center for Immunization Research Inpatient Unit, Mason F. Lord Building, 4940 Eastern Avenue, Baltimore, Maryland, United States

Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis

Completed

Conditions: Atopic Dermatitis

First Posted Date: 2007-08-13

Last Posted Date: 2014-04-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 900

Registration Number: NCT00515047

Locations: 🇺🇸
University of California at San Diego, La Jolla, California, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

and more 4 locations

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Phase 2

Terminated

Conditions: New-onset Type 1 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Antithymocyte globulin

First Posted Date: 2007-08-13

Last Posted Date: 2017-05-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 58

Registration Number: NCT00515099

Locations: 🇺🇸
Children's Hospital/USC School of Medicine, Los Angeles, California, United States
🇺🇸
Emory Children's Center, Atlanta, Georgia, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 6 locations

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Phase 2

Withdrawn

Conditions: Hermanski-Pudlak Syndrome
Colitis
Cytokines
Lymphocytes
Drug Evaluation

Interventions: Drug: Corticosteroids
Drug: Tacrolimus
Drug: Mesalamine
Drug: 6-Mercaptopurine
Drug: Infliximab
Drug: Adalimumab

First Posted Date: 2007-08-10

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00514982

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effect of Albendazole Dose on Treatment of Lymphatic Filariasis

Phase 2

Completed

Conditions: Lymphatic Filariasis

Interventions: Drug: Albendazole
Drug: Diethylcarbamazine

First Posted Date: 2007-08-03

Last Posted Date: 2015-08-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00511004

Locations: 🇮🇳
Filariasis Chemotherapy Unit (FCU), T.D. Medical Hospital, Alleppey, Kerala, India

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy